Inhibition of the acetyltransferases p 300 and CBP reveals a targetable function for p 300 in the survival and invasion pathways of prostate cancer cell lines

Department of Urology, Experimental Urology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria Laboratory of Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 77515 Olomouc, Czech Republic Institute of Legal Medicine, Innsbruck Medical University, Müllerstrasse 44, 6020 Innsbruck, Austria Department of Pharmacology and Molecular Sciences and Department of Oncology, Johns Hopkins University School of Medicine, 725 N. Wolfe Street, Baltimore, MD 21205, USA *Present address: Urological Research Institute, Università Vita-Salute San Raffaele, Via Olgettina 60, 20132 Milan, Italy

[1]  Lin-Feng Chen,et al.  Posttranslational modifications of NF-kappaB: another layer of regulation for NF-kappaB signaling pathway. , 2010, Cellular signalling.

[2]  Ruben Abagyan,et al.  Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. , 2010, Chemistry & biology.

[3]  J. D. den Dunnen,et al.  Genome-wide assessment of differential roles for p300 and CBP in transcription regulation , 2010, Nucleic acids research.

[4]  Z. Culig,et al.  Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells , 2010, Endocrine-related cancer.

[5]  E. Tajkhorshid,et al.  Functional Interplay between Acetylation and Methylation of the RelA Subunit of NF-κB , 2010, Molecular and Cellular Biology.

[6]  L. Kenner,et al.  Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. , 2009, Cancer research.

[7]  S. Agrawal,et al.  Inhibition of Lysine Acetyltransferase KAT3B/p300 Activity by a Naturally Occurring Hydroxynaphthoquinone, Plumbagin* , 2009, The Journal of Biological Chemistry.

[8]  C. Takimoto,et al.  Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes , 2009, Clinical Cancer Research.

[9]  P. Cole,et al.  Structure and chemistry of the p300/CBP and Rtt109 histone acetyltransferases: implications for histone acetyltransferase evolution and function. , 2008, Current opinion in structural biology.

[10]  Francis J Giles,et al.  Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. , 2008, Cancer letters.

[11]  S. Triezenberg,et al.  Curcumin inhibits herpes simplex virus immediate-early gene expression by a mechanism independent of p300/CBP histone acetyltransferase activity. , 2008, Virology.

[12]  Yi Zhang,et al.  New Nomenclature for Chromatin-Modifying Enzymes , 2007, Cell.

[13]  D. Tindall,et al.  Androgen deprivation increases p300 expression in prostate cancer cells. , 2007, Cancer research.

[14]  Yun-Jin Jung,et al.  Curcumin is an inhibitor of p300 histone acetylatransferase. , 2006, Medicinal chemistry (Shariqah (United Arab Emirates)).

[15]  E. Seto,et al.  Acetylation and deacetylation of non-histone proteins. , 2005, Gene.

[16]  D. Tindall,et al.  p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. , 2005, Cancer research.

[17]  Georg Bartsch,et al.  Interleukin‐6 regulation of prostate cancer cell growth , 2005, Journal of cellular biochemistry.

[18]  Stefan Schmidt,et al.  Cancer cell line identification by short tandem repeat profiling: power and limitations , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  Georg Bartsch,et al.  The androgen receptor co‐activator CBP is up‐regulated following androgen withdrawal and is highly expressed in advanced prostate cancer , 2004, The Journal of pathology.

[20]  E. Kalkhoven,et al.  CBP and p300: HATs for different occasions. , 2004, Biochemical pharmacology.

[21]  E. Rosen,et al.  Acetylation of Androgen Receptor Enhances Coactivator Binding and Promotes Prostate Cancer Cell Growth , 2003, Molecular and Cellular Biology.

[22]  Dominique Trudel,et al.  Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. , 2003, Cancer research.

[23]  E. Schwarz,et al.  NFκB: A Pivotal Transcription Factor in Prostate Cancer Metastasis to Bone , 2003, Clinical orthopaedics and related research.

[24]  D. Tindall,et al.  p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. , 2002, Cancer research.

[25]  P. Krammer,et al.  Tumor Immunology , 2018, Medical Immunology.

[26]  B. Aggarwal,et al.  Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines , 2001, Oncogene.

[27]  S. Srinivasula,et al.  Tumor necrosis factor alpha induces BID cleavage and bypasses antiapoptotic signals in prostate cancer LNCaP cells. , 2001, Cancer research.

[28]  V. Ogryzko,et al.  p300 and p300/cAMP-response Element-binding Protein-associated Factor Acetylate the Androgen Receptor at Sites Governing Hormone-dependent Transactivation* , 2000, The Journal of Biological Chemistry.

[29]  G. Koh,et al.  Lipopolysaccharide activates matrix metalloproteinase-2 in endothelial cells through an NF-kappaB-dependent pathway. , 2000, Biochemical and biophysical research communications.

[30]  Carlos Caldas,et al.  Mutations truncating the EP300 acetylase in human cancers , 2000, Nature Genetics.

[31]  D. Livingston,et al.  Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. , 2000, Genes & development.

[32]  D. Livingston,et al.  Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation , 1998, Nature.

[33]  M. Gerritsen,et al.  CREB-binding protein/p300 are transcriptional coactivators of p65. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[34]  K. A. Klein,et al.  Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice , 1997, Nature Medicine.

[35]  R. Fridman,et al.  Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). , 1995, Cancer research.

[36]  R. Rees,et al.  Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. , 1994, British Journal of Cancer.

[37]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.

[38]  D. Peeper,et al.  Metastasis mechanisms. , 2009, Biochimica et biophysica acta.

[39]  A. Baldwin,et al.  Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. , 2006, Oncogene.

[40]  A. Rabson,et al.  NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? , 2004, Journal of cellular biochemistry.

[41]  H. Klocker,et al.  The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. , 2003, The American journal of pathology.

[42]  C. Sawyers,et al.  NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. , 2002, Molecular and cellular biology.

[43]  C. N. Coleman,et al.  Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. , 1999, Oncogene.